Objective: We investigated the expression of CDKs and prognosis in breast cancer.
Materials and Methods: The Oncomine database examined CDK gene expressions in breast cancer. The prescient worth of CDKs in bosom malignant growth patients was analyzed utilizing the Kaplan-Meier Plotter. The expression changes of CDKs in tumor staging were analyzed in the GEPIA database. The role of CDKs in DNA replication and the cell cycle was analyzed utilizing the KEGG data set. Using the CBioPortal database, the association between CDKs gene expression and CDKs in breast cancer was investigated. The Encori database was used to study miRNAs that target CDKs.
Results: Oncomine data showed that the expressions of CDK1, CDK5 and CDK20 in breast cancer patients were upregulated, while mRNA expression levels in CDK2 and CDK6 decreased, and CDK3, CDK4 and CDK7~19 were not expression data. Results from the GEPIA database revealed that the expression levels of CDK1, CDK2, CDK4, CDK5, CDK7, CDK8, and CDK20 were greater in breast cancer tissues than in normal tissues, and that CDK1 and CDK5 were significantly different, and the expression levels of CDK3 and CDK1 in the former were lower than those in the latter, while those in the latter did not change. Kaplan-Meier Plotter data showed that CDK1, CDK3, CDK4 and CDK20 were associated with a dismal prognosis in individuals with breast cancer, while mRNA level in CDK8 was associated with progression after survival.
Conclusions: CDK1, CDK2c, CDK4, CDK5, CDK7, CDK8 and CDK20 can be used as molecular markers for breast cancer patients, or as potential targets for breast cancer therapy by targeting CDKs.
To cite this article
Clinical data analysis of CDKs expression and prognosis in breast cancer
Submission date: 20 Sep 2022
Revised on: 19 Oct 2022
Accepted on: 02 Jan 2023
Published online: 30 Jan 2023
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.